Tokyo, Japan

Masae Saitoh

This inventor holds 1 USPTO granted patent. Top assignee: Ludwig Institute for Cancer Research Limited. Active years: 2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masae Saitoh. Retrieved from https://idiyas.com/inventor/masae-saitoh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Masae Saitoh: Innovator in Cancer Research

Introduction

Masae Saitoh is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of cancer research, particularly through her innovative work on receptor variants.

Latest Patents

Masae Saitoh holds a patent for "Recombinant TGF-β type I receptor variants having differentially." This patent showcases her expertise and dedication to advancing scientific knowledge in her field. She has 1 patent to her name.

Career Highlights

Masae Saitoh is affiliated with the Ludwig Institute for Cancer Research Limited, where she continues to push the boundaries of cancer research. Her work has been instrumental in understanding the mechanisms of cancer and developing potential therapeutic strategies.

Collaborations

Masae has collaborated with notable colleagues, including Kohei Miyazono and Hidenori Ichijo. These partnerships have further enriched her research and contributed to the advancement of cancer therapies.

Conclusion

Masae Saitoh is a dedicated inventor whose work in cancer research is paving the way for future innovations. Her contributions are vital to the ongoing fight against cancer, and her patent reflects her commitment to this important field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…